PCI Pharma Services

Pre-clinical

Mannheim, GermanyFounded 1991pci.com

PCI Pharma Services is a premier global CDMO offering comprehensive end-to-end solutions for drug development, clinical trial supply, and commercial manufacturing. With a network of facilities across North America, Europe, and Australia, the company supports a diverse portfolio of therapies, including oncology, gene and cell therapies, and complex injectables. Its strategic focus on integrated services, regulatory expertise, and advanced technologies positions it as a critical partner in bringing innovative medicines to market efficiently and reliably.

Founded

1991

Employees

4000-5000

Focus

Drug Delivery

AI Company Overview

Technology Platform

Integrated CDMO services platform encompassing drug development, clinical trial supply, commercial manufacturing (sterile injectables, oral solids), packaging, and global logistics for pharmaceuticals and biologics.

Funding History

Total raised: $350M

PIPE$150MBlackstoneMar 15, 2021

Debt$200MGoldman SachsOct 15, 2020

Opportunities

Significant growth opportunities exist in the expanding market for outsourced biologics and advanced therapy manufacturing (cell/gene therapies), the increasing demand for integrated end-to-end CDMO services from virtual biotechs, and the industry-wide need for resilient, global supply chain solutions.

Risk Factors

Key risks include client concentration, operational and regulatory compliance challenges in complex manufacturing, integration difficulties from its acquisitive growth strategy, and intense pricing competition in the crowded CDMO marketplace.

Competitive Landscape

PCI competes with large public CDMOs like Catalent and Lonza, as well as numerous specialized firms. Its primary differentiation is a strong focus on integrated, end-to-end services from clinical development through commercial supply, particularly for complex injectables and biologics, positioning it as a strategic partner rather than just a vendor.